Ascentage Pharma Group International

ASPHFOTCHealthcare● Active

$4.53

$-0.17(-3.51%)

Market Cap$1.7B

P/E Ratio—

52W High$10.65

52W Low$4.53

Avg Volume3

Open$4.53

Beta0.65

Free Cash Flow Financials Revenue

Ascentage Pharma Group International (ASPHF) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

ASPHF · free cash flow · updated Jun 8, 2026

Core FCF metrics

ASPHF · FCF · TTM · margin & CAGR

Free cash flow was −$1.20B for FY2025 (fiscal year ending 2025-12-31), down 785.9% year-over-year The FCF margin was -214.9%.

FY2025 Free Cash Flow−$1.20B▼ -785.9% YoY

Trailing 12M (TTM)−$1.38Btrailing 4 quarters sum

FCF Margin-214.9%−$1.20B ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

ASPHF · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$1.17B(28M)−$1.20B▼ 785.9%-214.9%

FY2024−$111.4M(24M)−$135.6M▲ +82.7%-13.8%

FY2023−$726.1M(57M)−$782.9M▲ +8.7%-352.7%

FY2022−$653.9M(203M)−$857.2M▲ +17.6%-408.8%

FY2021−$604.7M(435M)−$1.04B▼ 21.0%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

ASPHF · P/FCF · FCF yield · FCF per share

Ascentage Pharma Group International (ASPHF) reported negative free cash flow of −$1.20B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

ASPHF · cash flow statement · operating / investing / financing

For FY2025, Ascentage Pharma Group International generated −$1.17B in operating cash flow and spent 28M in capital expenditures, yielding −$1.20B in free cash flow.

Operating Activities

−$1.17B

Cash from core business operations

2025-12-31

Investing Activities

−$1.00B

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$2.54B

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$1.17B) − |CapEx| (28M) = FCF (−$1.20B)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

ASPHF vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Ascentage Pharma Group InternationalYOU

ASPHF

−$1.20B-785.9%-214.9%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Ascentage Pharma Group International (ASPHF) reported free cash flow of −$1.20B for FY2025 (fiscal year ending 2025-12-31), down 785.9% year-over-year. The FCF margin was -214.9%.

Ascentage Pharma Group International has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 10 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

ASPHF free cash flow · 8 questions

Ascentage Pharma Group International free cash flow was −$1.20B for FY2025, down 785.9% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$1.38B.

ASPHF free cash flowASPHF FCFASPHF FCF 2025ASPHF free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Ascentage Pharma Group International · Ascentage Pharma Group International SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026